Quick browse by jurisdictions
IAM Licensing 250
The World's Leading Patent & Technology Licensing Lawyers
It is a pleasure to welcome you to IAM Licensing 250: The World’s Leading Patent and Technology Licensing Practitioners. Now in its second year, this title combines our annual in-depth look at key IP licensing issues around the world with detailed research on leading patent and technology licensing lawyers in 25 major jurisdictions.
Jim Haley is the former co-head of patents in the IP corporate group of Ropes & Gray. His practice focuses on the worldwide procurement and enforcement of patents in the biotechnology, biopharmaceutical and pharmaceutical industries. He has counselled biopharmaceutical clients since 1978 and drafted, prosecuted and defended some of the basic patents in biotechnology. Those patents have garnered over US$4 billion in royalties.Some of Mr Haley’s representative infringement cases include Shelbyzyme v Genzyme (D Del), Genzyme v Anika Therapeutics (D Mass), Genzyme v Zimmer (D Mass), Pieczenik v Abbott (D NJ), MEEI v QLT/Novartis Ophthalmics (D Mass), MEEI v QLT (D Mass), ...
The Washington DC Metropolitan Area is a key market for patent and technology licensing. The proximity of the International Trade Commission, the US Patent and Trademark Office and the Court of Appeals for the Federal Circuit make it a thriving centre for patent litigation. As a direct result, substantial volumes of licensing activity are taking place in the resolution of such disputes. A number of leading licensing practitioners thus combine litigation and transactional expertise to good effect. The federal government is one of the largest consumers of technology in the world and has contributed hugely to the licensing landscape in the district. Its provision of funding for ...
The US Supreme Court and the en banc Court of Appeals for the Federal Circuit (CAFC) have addressed the law on patent validity and enforceability in two recent decisions. In so doing they have added clarity and predictability to the value of US patent portfolios in a way that should facilitate IP monetisation and expedite IP transactions.